NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Core Viewpoint - NeuroThera Labs Inc. has advanced its collaboration with Clearmind Medicine Inc. by publishing an international patent application for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2]. Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [4]. - Clearmind Medicine Inc. is a clinical-stage neuroplastogens pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for widespread health issues, including alcohol use disorder [5]. Market Potential - The combination therapy of 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) is positioned to address obesity, which affects over 890 million adults globally, and MASLD, impacting approximately 30% of the global adult population [2]. - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists [3]. Therapeutic Advantages - The MEAI-PEA combination may provide a safer, non-hallucinogenic neuroplastogen treatment option that is potentially more cost-effective than existing GLP-1 agonists for obesity and MASLD [2][3]. - The collaboration aims to meet the growing demand for effective, tolerable, and safe treatments in the obesity and liver health sectors [3].